CA-MHL-LLC
MHL, LLC today announced that more than 650 million MHL® products have shipped worldwide since the first MHL-enabled products were released in 2011. The world’s leading consumer electronics and mobile device companies continue to release exciting new MHL-enabled products that showcase the power of MHL technology, which brings HD multimedia content from a mobile device to a larger screen. The global MHL ecosystem includes adapters, automotive accessories, A/V receivers, Blu-ray Disc™ players, cables, DTVs, monitors, projectors, smartphones, streaming media sticks, tablets and more.
A steady stream of MHL 3.0 mobile devices that output 4K Ultra HD video have been released this year, including the Samsung Galaxy Note 4, Sony Xperia Z2 and Z3, and ZTE nubia Z7, along with MHL 3.0 4K Ultra HD displays from Samsung and Sony. 4K is rapidly growing in popularity and, with these MHL 3.0 smartphones, consumers can capture brilliant photos and videos and then enjoy them in full 4K Ultra HD beauty on their big screen TV.
MHL has also achieved broader adoption in emerging markets such as India and China where smartphone shipments are rapidly accelerating. In these areas, consumers want more out of their smartphones – taking them beyond communication devices and transforming them into gaming consoles, powerful PCs and entertainment systems. The ability to connect a smartphone or tablet to the big screen to display photos and videos, play games or use productivity applications is a compelling value proposition, which continues to expand the adoption of MHL in emerging markets.
“When we released the first MHL specification, we started with a simple idea of connecting a phone to a TV. This has now evolved into an advanced world of connectivity,” said Rob Tobias, president, MHL, LLC. “Our product ecosystem has rapidly grown and the use cases continue to expand, making MHL the world’s most widely adopted mobile TV-out standard and the de-facto connectivity between mobile, consumer electronics and automotive products.”
A World of Possibilities with MHL:
Stay: Watch movies and view photos from the comforts of home all while using the TV’s remote control to access the mobile device’s content. Home entertainment has never been easier.
Play: Experience mobile gaming on a larger screen with no lag, all while the TV provides power to the smartphone or tablet for extended game play.
Away: Transform a mobile device into a portable computer by connecting it to a keyboard, mouse, monitor (or multiple monitors) and storage device to work anytime, anywhere.
For more information about the MHL Consortium, how to become an adopter, or to see a full list of MHL products, please visit: http://www.mhltech.org .
Follow MHL on Twitter
.
Like
MHL on Facebook
.
Learn
more about MHL technology on YouTube
.
Stay
up to date on Google+
.
About MHL, LLC
MHL, LLC is the Agent for overseeing and administering the adoption, licensing, and promotion of the MHL Specification. The MHL Specification was developed by Nokia Corporation, Samsung Electronics Co., Ltd., Silicon Image, Inc., Sony Corporation, and Toshiba Corporation as a standard for mobile wired video/audio connectivity, which will enable the development of standard-compliant mobile and display products across a broad connectivity ecosystem. MHL, LLC is a wholly owned subsidiary of Silicon Image, Inc. For more information please visit http://www.mhltech.org .
Forward-looking Statements
This news release contains forward-looking statements within the meaning of United States federal securities laws and regulations, including, but not limited to, statements regarding the growth in the market size and adoption and the features, functionality, performance, advantages and benefits of the MHL 3.0 specification, MHL technology and MHL-enabled mobile and display devices as well as the future of mobile entertainment and productivity. These forward-looking statements involve risks and uncertainties, including, but not limited to, the risks and uncertainties described from time to time in Silicon Image’s filings with the Securities and Exchange Commission (SEC). These risks and uncertainties could cause the actual results to differ materially from those anticipated by the forward-looking statements contained in this news release. Silicon Image assumes no obligation to update any forward-looking statement.
MHL and the MHL logo are a trademark, registered trademark or service mark of MHL, LLC in the United States and/or other countries. All other trademarks and registered trademarks are the property of their respective owners in the United States and/or other countries.
Contact:
MHL, LLC
Kristin Uchiyama, +1-408-962-4280
kristin@mhltech.org
or
Racepoint
Global
Allison DeLeo, +1-415-694-6711
adeleo@racepointglobal.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum